Octahydro Cyclopenta (B) Pyrrole-2-Benzyl Carboxylate Hydrochloride

Industrial-scale production of ramipril under full ICH Q7 adherence initiates with the quantitative neutralisation of the hydrochloride salt using 1.08–1.12 molar equivalents of N,N-diisopropylethylamine in ethyl acetate at −10 °C to −5 °C. The liberated benzyl ester free base is immediately reacted with (S)-N-[(1-ethoxycarbonyl)-3-phenylpropyl]-L-alanine via the mixed carbonic anhydride method employing isobutyl chloroformate, the activation step requiring a residence time of 45–60 seconds in a 500 L glass-lined cryogenic reactor equipped with a 0.2 µm inline PTFE filter. The molar ratio of the benzyl ester intermediate to the alanine derivative is maintained at 1.00:1.05 to compensate for minor ester hydrolysis; excursions beyond 1.00:1.10 result in quantifiable carry-over of the alanine precursor into the crude ramipril ethyl ester, necessitating an additional 18–22 h recrystallization step from methyl tert-butyl ether/n-heptane (2:1 v/v) to restore compliance with the Ph. Eur. monograph 01/2024:1397. The compliance framework governing the final API also includes USP monograph USP-NF 2024 and ICH M7 for mutagenic impurity control. Residual water content above 0.05% w/w in the solvent system promotes premature hydrolysis of the mixed anhydride, directly increasing the des-benzyl acid impurity above the 0.10% specification threshold. The downstream process culminates in ramipril API, which is subsequently formulated into 2.5 mg, 5 mg, and 10 mg uncoated tablets or hard gelatin capsule dosage forms for essential hypertension management.

What Determines the Diastereomeric Purity Threshold in the Manufacture of Ramipril?

The sole pharmacologically acceptable stereochemistry—(2S,3aS,6aS)-configuration—imposes an asymmetric integrity requirement on the starting intermediate. The benzyl ester hydrochloride must exhibit a diastereomeric excess of ≥99.5% when assayed by chiral HPLC (Chiralpak IA column, 250 × 4.6 mm, 5 µm particle size, hexane/ethanol/diethylamine 90:10:0.1 v/v/v) against a reference standard certified against Ph. Eur. 01/2024:1397. A (2R,3aR,6aR)-isomer content exceeding 0.3% w/w leads to a ramipril batch that fails the chromatographic purity test under standard C18 reverse-phase conditions described in the same monograph, as the non-physiologically active enantiomer co-elutes with the main peak. In commercial production, the downstream synthesis process incorporates a diastereomeric salt resolution step using (−)-di-p-toluoyl-L-tartaric acid in acetonitrile/water (7:3 v/v) prior to benzyl esterification; for those intermediates sourced externally, a dedicated pre-coupling recrystallization from 2-propanol/n-heptane (3:7 v/v) is mandated when chiral purity falls below 99.0%. This resolution step adds 6–8 h to the campaign cycle time in a 1000 L cylindrical vessel with retreat-curve impeller agitation at 80 rpm. The terminal dosage form remains ramipril tablets, and compliance is audited against ICH Q6A decision tree #2 for chiral identity and strength.

Proline-Mimetic Fragment Incorporation in Fmoc-SPPS of Conformationally Constrained Peptide Analogues

In medicinal chemistry campaigns targeting bradykinin B2 receptor antagonists, the octahydrocyclopenta[b]pyrrole-2-carbonyl (OCP) residue functions as a proline surrogate that restricts the pyrrolidine ring pucker and shifts the cis/trans ratio of the Xaa-OCp amide bond to above 4:1 trans under aqueous coupling conditions. The hydrochloride salt is pre-neutralised with 5.0 molar equivalents of N,N-diisopropylethylamine relative to the resin loading (typically 0.25 mmol/g on a Tentagel S RAM resin) prior to activation with HCTU (1-[(bis(dimethylamino)methylene]-5-chloro-1H-benzotriazolium 3-oxide hexafluorophosphate) and a 0.4 M coupling cycle of 45 min at 60 °C under microwave-assisted conditions (CEM Liberty Blue™). The incorporation ratio, expressed as acylation completeness monitored by the bromophenol blue test, must exceed 99.3% to prevent deletion sequences in the final 15-mer peptide; double coupling with a 7.0 equivalent excess is required for sterically hindered residues immediately downstream of the OCP fragment. While no compendial monograph governs this research intermediate, the synthesis aligns with the quality system requirements for research-grade biochemical reagents under an ISO 9001:2015 certified facility. The resulting peptide—such as H‑Arg‑Pro‑Hyp‑Gly‑Thi‑Ser‑OCp‑Tic‑Oic‑Arg‑OH—is isolated by semi-preparative RP‑HPLC and lyophilised to a final purity of ≥95% for in vitro receptor-binding and metabolic stability assays.

Forced degradation studies prescribed in ICH Q3B and required for ramipril ANDA submissions necessitate a fully characterised reference standard of the diketopiperazine impurity (ramipril impurity A, Ph. Eur. 01/2024:1397). The synthesis begins with head-to-tail cyclisation of the benzyl ester intermediate after deprotection and coupling with the N-terminal fragment. Precisely 10 mmol of the hydrochloride is converted to the free amine with 10 mL of 10% aqueous sodium carbonate and extracted into dichloromethane; it is then mixed with 10.5 mmol of the ethyl ester precursor in refluxing toluene for 12 h in the presence of 1.1 equivalents of 1-hydroxybenzotriazole hydrate. The crude cyclised product is purified using a Waters AutoPurification™ system fitted with an XBridge C18 OBD column (30 × 150 mm, 5 µm), employing a linear gradient of acetonitrile/0.1% trifluoroacetic acid from 30% to 70% over 20 min. The impurity reference compound is collected in peak-based fractions, lyophilised, and dispensed into 20 mg amber vials sealed under argon. This material serves as the system suitability marker for HPLC purity release testing of ramipril 10 mg finished dosage forms, and its batch certificate includes qNMR-assigned potency conforming to ICH Q6A expectations for reference standards.

When Direct-Compression Grade Ramipril Requires Predefined Crystal Habit via Intermediate Engineering

The tabletability of ramipril is notoriously sensitive to the crystal morphology of the active substance, with needle-shaped habits causing poor flow (Carr index >30) and lamination on high-speed rotary presses such as the Korsch XL 400 at 80 rpm. By strictly controlling the solvent composition during the final recrystallisation of the benzyl ester intermediate—specifically, the ratio of ethyl acetate : cyclohexane adjusted to 62:38 v/v and the cooling rate limited to 0.3 °C/min—one indirectly templates the nucleation of the subsequent ramipril free acid into equant particles with a volume-weighted mean diameter D[4,3] ≈ 120 µm and a span value below 1.6. The addition ratio of the hydrochloride intermediate to the solvent system is 1:8 w/v, and the recovery step is executed in a 2000 L unbaffled crystalliser under continuous 150 rpm pitch-blade stirring. A deviation in the cooling ramp exceeding 0.5 °C/min triggers plate‑like growth and increases the proportion of fines passing a 75 µm screen to above 18%, rendering the batch unsuitable for direct compression. The FDA 21 CFR 211.110 requirement for in-process blending uniformity testing becomes readily achievable without wet granulation, shortening the overall tablet manufacturing process by 2–3 working days and eliminating the need for fluid bed drying. The final dosage form is a ramipril 10 mg uncoated immediate-release tablet with a specified dissolution tolerance of Q ≥80% in 30 min at pH 4.5 as per USP 〈711〉.

Process validation batches for ramipril active ingredient produced under an FDA-reviewed Type II DMF require a demonstration of impurity purging factors across the synthetic sequence. Using the benzyl ester hydrochloride at a 1.00:1.04 molar charge ratio relative to the N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanine fragment in a 200 L Hastelloy C‑22 reactor, spiking experiments at the 10 kg scale show that residual benzyl alcohol formed from ester hydrolysis is removed to below 0.05% w/w by two sequential agitated washes with 8% aqueous sodium bicarbonate solution (2 × 150 L, each wash with a 15‑min contact time at 25 °C). The test is conducted according to a validation protocol aligned to ICH Q2(R2) for trace-level quantitation, with an LOD of 10 ppm and LOQ of 30 ppm for benzyl alcohol by headspace GC‑FID. The final product—ramipril EP‑grade—is released with an internal specification of benzyl alcohol ≤0.03% and employed directly in the manufacture of size 3 hard gelatin capsules containing 5 mg of active blended with pregelatinised starch NF.